NCT04910152View on ClinicalTrials.gov

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions

Acute Graft Versus Host DiseaseSteroid Refractory Graft Versus Host Disease

Interventions

DRUG

BRD4 Inhibitor PLX51107

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Plexxikon

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Hannah Choe, MD

OTHER